Object Pharma and Poland's TZF Polfa announce a strategic collaboration to advance next‑generation neuromodulator therapeutics for major depressive disorder, combining Object Pharma's research expertise with TZF Polfa's manufacturing strength to accelerate clinical development and global market readiness.
ALISO VIEJO, Calif., April 1, 2026 /PRNewswire-PRWeb/ -- Object Pharma, a preclinical biopharmaceutical company developing novel therapeutics for major depressive disorder (MDD) and related mental health conditions, today announced it has entered into a collaboration agreement with TZF Polfa, the oldest Polish pharmaceutical company, to advance Object Pharma's innovative neuromodulator mental health treatment.
The collaboration combines Object Pharma's neuromodulator development expertise with TZF Polfa's manufacturing capabilities and European market knowledge as the companies together explore opportunities to advance next-generation therapeutics for major depressive disorder and other psychiatric conditions.
"Our work with TZF Polfa represents important groundwork in Object Pharma's mission to transform mental health care," said Kenton Abel, Chief Executive Officer of Object Pharma. "TZF Polfa's experience in pharmaceutical production and international distribution complements our deep research and clinical expertise, allowing us to move promising compounds toward patients more efficiently and cost effectively."
The announcement comes as Object Pharma advances its $35 million Series A financing round, which is attracting strategic investors and family offices interested in novel approaches to treating mental health disorders. The funds will support planned clinical programs and expanded research initiatives within the new collaboration framework.
"We are pleased to partner with Object Pharma on this important initiative," said Maksymilian Åšwiniarski, CEO of TZF Polfa. "Mental health is not only a critical area of unmet medical need, but also a foundational pillar of societal resilience. Strengthening mental health outcomes goes hand in hand with ensuring long-term drug security and system stability. At TZF Polfa, we see this collaboration as an opportunity to contribute to both - by supporting the development of innovative therapies that enhance patient wellbeing while reinforcing the broader resilience of healthcare systems."
About Object Pharma:
Object Pharma is a late preclinical stage biopharmaceutical company focused on developing novel neuromodulator therapeutics for mental health and neurological conditions, including major depressive disorder, general anxiety, and postpartum depression. The company integrates advanced pharmacology, clinical design, and translational neuroscience to deliver precision-based treatments that improve patient outcomes.
About TZF Polfa:
TZF Polfa information: Established in 1823, TZF Polfa S.A., is a leading European generic pharmaceutical company known for its broad manufacturing capabilities and commitment to advancing healthcare through science-driven innovation. Based in Warsaw, the company employs more than 950 professionals. Majority shareholder is Ministry of State Assets
Media Contact
Dennis Fluet, Object Pharma, 1 (949) 269-3260 0, [email protected],
Katarzyna Miltrovic, TZF Polfa, 48 573262 516, [email protected],
SOURCE Object Pharma
Share this article